Clearmind Seeks FDA Breakthrough Therapy Designation for MEAI After Positive Phase I/IIa Results
Clearmind Medicine is evaluating its non-hallucinogenic candidate CMND-100 (MEAI) for FDA Breakthrough Therapy Designation after Phase I/IIa Alcohol Use Disorder trial showed positive clinical results. A recent Executive Order accelerates FDA review for psychedelic and neuroplastogen therapies, potentially speeding regulatory progress for CMND-100.
1. Evaluation for Breakthrough Therapy Designation
Clearmind Medicine has initiated an internal assessment of CMND-100 (MEAI) to determine its suitability for FDA Breakthrough Therapy Designation based on preliminary clinical evidence, though no formal request has yet been submitted.
2. Phase I/IIa Alcohol Use Disorder Trial Results
The ongoing FDA-approved Phase I/IIa trial for Alcohol Use Disorder demonstrated positive clinical outcomes on key endpoints, suggesting CMND-100 may offer substantial improvement over existing treatment options for a condition affecting millions.
3. Executive Order Accelerates Review
A recent Executive Order signed by President Trump directs FDA to expedite review of psychedelic and neuroplastogen therapies granted breakthrough status, potentially shortening regulatory timelines for CMND-100’s designation process.
4. Next Steps and FDA Engagement
Clearmind plans to continue discussions with FDA, finalize its Breakthrough Therapy request strategy, and leverage its portfolio of 19 patent families to support CMND-100’s development and commercialization pathway.